Samsung Pharm Co Ltd

Samsung Pharm Co Ltd maintains a capital structure with a debt-to-equity ratio of 0.15, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 0.92, suggesting that its current liabilities slightly exceed its current assets. The company's price-to-book ratio is 1.42, and its price-to-tangible-book ratio is also 1.42, indicating that the market values the company at a premium to its tangible book value. Profitability metrics show a return on equity (ROE) of 9.54% and a return on assets (ROA) of 6.9%, which are key indicators of the company's efficiency in generating profits from its equity and total assets. These figures are to be compared against the industry's preferred metrics and cohort medians to assess relative performance. The company's revenue is distributed across two segments: the Pharmaceutical and Quasi-drug Sale Business and the Health Food Manufacturing and Sale segment. The exact revenue concentration within these segments is not disclosed, but the company's operations are primarily based in South Korea, with no significant geographic diversification mentioned in the available data. Samsung Pharm Co Ltd's growth trajectory is reflected in its financial outlook, with a current fiscal year (FY) and next FY direction to be analyzed using numeric deltas and revenue history. The company's operating income is negative at -20,627,369,610 KRW, indicating a decline in profitability, which may affect its growth prospects. Risk factors for Samsung Pharm Co Ltd include a medium liquidity risk, as indicated by the risk assessment, and a low dilution potential. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The dilution potential is low, suggesting that the company is not expected to issue additional shares in the near term. Recent events and filings for Samsung Pharm Co Ltd include a change in the company's name from Samsung Pharmaceutical Co., Ltd. to Samsung Pharm Co Ltd. No recent transcripts or filings have been disclosed that would significantly impact the company's operations or financial position.